featured
Neratinib + Capecitabine Sustains HRQoL in Patients With HER2+ MBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neratinib + Capecitabine Sustains Health-Related Quality of Life in Patients With HER2-Positive Metastatic Breast Cancer and ≥ 2 Prior HER2-Directed Regimens
Breast Cancer Res Treat 2021 Apr 28;[EPub Ahead of Print], B Moy, M Oliveira, C Saura, W Gradishar, SB Kim, A Brufsky, SA Hurvitz, L Ryvo, D Fagnani, S Kalmadi, P Silverman, S Delaloge, J Alarcon, A Kwong, KS Lee, PCS Ang, SGW Ow, SC Chu, R Bryce, K Keyvanjah, J Bebchuk, B Zhang, N Oestreicher, R Bose, N ChanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.